Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) EBITDA (2017 - 2019)

Historic EBITDA for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' EBITDA fell 3539.27% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.2 million, marking a year-over-year decrease of 3885.63%. This contributed to the annual value of -$4.2 million for FY2019, which is 3105.32% down from last year.
  • Latest data reveals that Monopar Therapeutics reported EBITDA of -$1.2 million as of Q4 2019, which was down 3539.27% from -$744819.0 recorded in Q3 2019.
  • Monopar Therapeutics' EBITDA's 5-year high stood at -$373839.0 during Q1 2017, with a 5-year trough of -$14.9 million in Q3 2017.
  • Its 3-year average for EBITDA is -$2.0 million, with a median of -$810583.0 in 2018.
  • Data for Monopar Therapeutics' EBITDA shows a peak YoY increase of 9569.14% (in 2018) and a maximum YoY decrease of 13441.83% (in 2018) over the last 5 years.
  • Quarter analysis of 3 years shows Monopar Therapeutics' EBITDA stood at -$713583.0 in 2017, then fell by 24.79% to -$890472.0 in 2018, then crashed by 35.39% to -$1.2 million in 2019.
  • Its last three reported values are -$1.2 million in Q4 2019, -$744819.0 for Q3 2019, and -$904633.0 during Q2 2019.